SPARK Advisory Partners Limited (“SPARK”) is pleased to announce it has acted as Financial and Nominated Adviser to Belluscura plc (“BELL”) in respect of its initial public offering raising £17.5 million.
Based in Texas, Belluscura is a leading medical device developer focused in lightweight and portable oxygen enrichment technology. Its first product, the X-PLO₂R, is a lightweight FDA cleared portable oxygen concentrator (“POC”) designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO₂R weighs less than 1.5kg (3.25lbs) and is the world’s first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other FDA cleared POC in its class. The X-PLO₂R can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease (“COPD”) and respiratory distress caused by COVID-19. The X-PLO₂R will be launched shortly and additional products within the range will be launched within the next 12 months.